15 March 2018

Verona Pharma to Present at Upcoming Healthcare Investor Conferences

LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company management will present at three upcoming investor conferences:

Event: 28th Annual Oppenheimer Healthcare Conference
Date: March 21, 2018
Time: 3:55 PM EDT
Location: New York, NY

Event: Needham & Co. Annual Healthcare Conference
Date: March 27, 2018
Time: 12:15 PM EDT
Location: New York, NY

Event: H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2018
Time: 2:35 PM CEST
Location: Monte Carlo, Monaco

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

 
For further information, please contact:
 
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com 
   
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison SNELVeronaPharma@stifel.com 
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins  veronapharma@fticonsulting.com 
   
ICR, Inc. (US Media and Investor enquiries)  
James Heins Tel: +1 203-682-8251
  James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
  Stephanie.Carrington@icrinc.com 

 

Primary Logo

 

Source: Verona Pharma plc


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us